About Us


"Our ability to continuously scale new heights across the biopharmaceutical value chain enables us to realise the promise of future therapeutics." -Kiran Mazumdar-Shaw, Chairman & Managing Director


Biocon is a fully integrated healthcare company that delivers innovative biopharmaceutical solutions. From discovery to development and commercialisation, we have the defining science, cost-effective drug development capabilities and significant manufacturing capacity to move ideas to market.

Leveraging India’s globally competitive cost base and exceptional scientific people resource, we are advancing our in-house R&D programs, while also providing custom and clinical research services to international pharmaceutical and biotechnology majors through our subsidiary companies, Syngene and Clinigene.

Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and several other molecules at exciting stages in the biopharmaceutical value chain. With the successful commercial launch of our first anti-cancer drug and several promising discovery partnerships in the clinic, we remain committed to scaling new heights in frontier science and achieving new milestones in affordable medicine.

The Innovation Matrix: A Strategic Framework

Click here to enlarge

To navigate the challenges of innovation in the next decade we have adopted a well-defined strategic framework that will transform scientific discoveries into advances in human healthcare and generate incremental value for our shareholders.

Our Innovation Matrix is a four-dimensional endeavour which extends into the realms of the known and the unknown. Creativity in the known realm builds on existing knowledge and can result in two types of innovation: INCREMENTAL and EVOLUTIONARY. Creativity that challenges unknown boundaries and creates new knowledge is EXPERIMENTAL and TRANSFORMATIONAL in its impact. A portfolio that covers all four spheres enables Biocon to sustain innovation in the short, medium and long term.

Our biosimilar insulin, an outcome of incremental innovation, is one of the world’s most affordable therapies for insulin dependent diabetes. Bio-generic monoclonal antibodies are forming the core of our evolutionary innovation strategy. In the more challenging area of experimental innovation, Biocon is at the cutting edge. We are developing conjugated antibodies with a US Biotech start-up, IATRICa, to potentially deliver therapeutic cancer vaccines. We are also pursuing a path of breakthrough innovation through phase III human clinical trials to develop the world’s first Oral Insulin. Biocon is thus rapidly moving towards commercializing novel biologics with a "Made in India" label.